- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01618344
Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer
Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
1)15-29 year olds receiving treatment for any type of cancer, either primary or recurrent/relapsed disease.
2) Patient has completed at least one month of therapy
3)Patient is expected to remain on therapy for 3 month duration of study
4) Patient has an iPhone, iPad, or iTouch running iOS 4.0 or later
5) Patient is willing to use a smart-phone medication reminder application-
Exclusion Criteria:
1)Patients who are unable to speak/read/write English as required for use of smart-phone medication reminder application and completion of study measures.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility and Acceptability of Using a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by AYA With Cancer.
Time Frame: ongoing study weeks 5-12
|
Feasibility was assessed through participants' application usage and responses to self-reported questions about their use of the application.
Acceptability was assessed through participants' perceived ease of use and perceived usefulness of the application.
|
ongoing study weeks 5-12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yelena Wu, PhD, Huntsman Cancer Institute
- Principal Investigator: Lauri Linder, PhD, University of Utah
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCH-13929
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
Peking University First HospitalRecruitingBreast Neoplasms、Lung Neoplasms、Pancreatic NeoplasmsChina
-
Hospices Civils de LyonNot yet recruiting
-
GlaxoSmithKlineCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ain Shams UniversityNot yet recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Medical College of WisconsinM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Chicago and other collaboratorsRecruiting
-
GlaxoSmithKlineRecruitingNeoplasms, ColonSpain, Belgium, Japan, Italy, United Kingdom, Switzerland